Nebula Genomics, the startup that wants to put your whole genome on the blockchain, has announced the $ 4.3 million increase in the Series A by Khosla Ventures and other technology VCs such as Arch Venture Partners, Fenbushi Capital, Mayfield, F- Prime Capital Partners, Great Point Ventures, Windham Venture Partners, Hemi Ventures, Mirae Asset, Hikma Ventures and Heartbeat Labs.
Nebula also partnered with the Veritas Genetics genome sequencing company.
Veritas was one of the first companies to sequence the entire human genome for less than $ 1,000 in 2015, subsequently adding all the information at the touch of a button on your smartphone. Both Nebula and Veritas were co-founded by the MIT professor and "godfather" of the Human Genome Project, George Church.
The partnership between the two companies will allow the Nebula market or the place where those who consent to share their data genetics can earn the cryptocurrency of Nebula called "token Nebula" to build on the Veritas software platform open- source Arvados, which can process and share large amounts of genetic information and other large data. According to the company, this crossover offers privacy and security for physical storage and management of various data sets according to local rules and regulations.
"As our database grows to many petabytes, together with the Nebula team we are taking the In our industry, to protect consumer privacy and enable them to participate in research and benefit from the blockchain-based market, Nebula is building" , stated Veritas CEO Mirza Cifric in a statement.
The partnership will work with various academic institutions and industry researchers to provide genomics data from individual consumers trying to cash in by sharing their data, rather than giving them freely as they could through another genomics company like 23andMe .
"Compared to centralized databases, Nebula is decentralized and federated architecture will help address privacy issues and encourage data sharing," added Nebula Genomics co-founder. it's Grishin. "Our goal is to create a flow of data that will accelerate medical research and catalyze a transformation of health care."